PMID- 25944843
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20220331
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 21
IP  - 1
DP  - 2016 Jan
TI  - A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo 
      Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An 
      Experimental Study Utilizing Porcine Model of In-Stent Restenosis.
PG  - 93-9
LID - 10.1177/1074248415583091 [doi]
AB  - OBJECTIVES: We aimed to comprehensively evaluate poly-lactide polymer degradation 
      and sirolimus release kinetics from a drug-eluting stent matrix in the in vivo 
      setting using a nuclear magnetic resonance (NMR) method. METHODS: In 22 domestic 
      swine, 18 biodegradable polymer-only coated stents (BPSs) and 36 biodegradable 
      polymer-coated sirolimus-eluting stents (BP-SES) were implanted in coronary 
      arteries with 115% overstretch. The animals were sacrificed at 1, 3, 7, 14, 28, 
      and 56 days following baseline procedures. Vessel segments with BPS were 
      harvested to evaluate polymer degradation with a NMR method, whereas BP-SES to 
      analyze sirolimus tissue uptake and retention. Additionally, 8 BP-SES were 
      implanted for histological analysis for 90 days of follow-up. RESULTS: The NMR 
      showed a gradual absorption of the polymer over the 6 consecutive time points, 
      from 5.48 microg of the polymer on the stent at 1-day follow-up, through 4.33 microg at 3 
      days, 3.16 microg at 7 days, 2.42 microg at 14 days, 1.92 microg at 28 days to 1.24 microg in the 
      last day of the study. The curve of polymer degradation corresponds well with the 
      pharmacokinetic profile of sirolimus eluted from its surface and measured at 
      identical time points. In histopathology, at 90 days, complete healing and 
      biocompatibility were reported. CONCLUSIONS: The utilization of NMR method for BP 
      absorption kinetics evaluation is a useful tool, which may be widely adopted to 
      test other biodegradable implants. Further, it may substantially improve their 
      safety and efficacy by facilitating programmed polymer and drugs elution.
CI  - (c) The Author(s) 2015.
FAU - Orlik, Bartlomiej
AU  - Orlik B
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Buszman, Piotr P
AU  - Buszman PP
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland Third Clinical Department of Cardiology, Silesian Center for 
      Heart Diseases, Zabrze, Poland.
FAU - Krauze, Agata
AU  - Krauze A
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Gasior, Pawel
AU  - Gasior P
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Desperak, Piotr
AU  - Desperak P
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Pajak, Jacek
AU  - Pajak J
AD  - Department of Histopathology, Medical University of Silesia, Katowice, Poland.
FAU - Kasperczyk, Janusz
AU  - Kasperczyk J
AD  - Center of Polymer and Carbon Materials, Polish Academy of Sciences, Zabrze, 
      Poland.
FAU - Janas, Adam
AU  - Janas A
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Jelonek, Michal
AU  - Jelonek M
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Handzlik-Orlik, Gabriela
AU  - Handzlik-Orlik G
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Buszman, Pawel E
AU  - Buszman PE
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland.
FAU - Milewski, Krzysztof
AU  - Milewski K
AD  - Center for Cardiovascular Research and Development, American Heart of Poland, 
      Katowice, Poland k.milewski@ahp-ccrd.org.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150505
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Polyesters)
RN  - 459TN2L5F5 (poly(lactide))
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Absorbable Implants
MH  - Animals
MH  - Cardiovascular Agents/administration & dosage/*pharmacokinetics
MH  - Coronary Restenosis/*therapy
MH  - Disease Models, Animal
MH  - *Drug-Eluting Stents
MH  - Female
MH  - *Magnetic Resonance Spectroscopy
MH  - Male
MH  - Percutaneous Coronary Intervention/*instrumentation
MH  - Polyesters/*chemistry
MH  - Prosthesis Design
MH  - Sirolimus/administration & dosage/*metabolism/pharmacokinetics
MH  - Sus scrofa
OTO - NOTNLM
OT  - NMR spectroscopy
OT  - biodegradable polymer
OT  - coronary stents
OT  - porcine model
OT  - sirolimus-eluting stent
EDAT- 2015/05/07 06:00
MHDA- 2016/09/27 06:00
CRDT- 2015/05/07 06:00
PHST- 2014/11/11 00:00 [received]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/05/07 06:00 [entrez]
PHST- 2015/05/07 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - 1074248415583091 [pii]
AID - 10.1177/1074248415583091 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):93-9. doi: 10.1177/1074248415583091. 
      Epub 2015 May 5.